The next four years may be the hottest for medical marijuana, and many experts are expecting a big jump in sales.
“We are seeing a real shift in opinion on medical marijuana in the US, and there is a lot of enthusiasm for it,” says Andrew Leach, executive director of the Medical Marijuana Policy Project, a coalition of medical marijuana advocates.
“There are a lot more patients using it, and they are getting better.”
The industry is also seeing a boom in advertising campaigns.
As the number of states legalize recreational marijuana sales, pharmaceutical companies are spending millions on advertisements to promote their products, and some are even partnering with medical marijuana companies to create a new cannabis strain to market to the public.
As a result, medical marijuana sales are expected to reach $30 billion in 2019, according to an estimate by the National Cannabis Industry Association, a trade group.
But some say the real boost may come from a new strain of marijuana that may one day find its way into the hands of people with chronic pain.
In an article published Tuesday in The Wall Street Journal, researchers from the University of Colorado and University of Utah published a study that found people with arthritis are more likely to take a cannabis strain that has been tested to treat their symptoms than a placebo.
The study also found that people with multiple sclerosis who were prescribed marijuana for their condition reported higher rates of pain relief and improved quality of life than people who received placebo.
It’s the first to compare marijuana with other therapies for chronic pain and finds that people who were given the marijuana had fewer side effects and had better overall outcomes.
“These results indicate that people using medical marijuana are more than just being given the same cannabis that we see in other treatments,” said lead author Dr. Eric Zeng, an assistant professor of medicine at the University at Albany.
“They are being given a cannabis that has proven to work in a variety of different diseases.”
Zeng and his team conducted a randomized clinical trial of marijuana, using patients with moderate to severe arthritis and chronic pain to see if it could treat symptoms in people with a variety, but not all, of the conditions.
The trial included 5,000 people who had severe arthritis, 4,500 with mild to moderate pain, and 1,000 with moderate or mild pain.
The researchers used a “placebo control” group.
The people who took the marijuana received a placebo and a placebo capsule in a glass vial containing marijuana oil.
The marijuana oil, called Cannabidiol, is derived from the cannabis plant and contains a small amount of THC.
The Cannabids are not a drug or a drug metabolite like THC, which has a high concentration in the body, but rather a natural plant compound.
They were administered in an open-label, placebo-controlled trial to compare the effects of Cannabida with the effects on the body of the THC.
In addition to finding that the marijuana helped relieve pain, it was shown to relieve some other symptoms, such as nausea and fatigue.
Zeng says the results are promising and suggests that there may be other potential therapies for patients with chronic conditions that aren’t being explored with cannabis.
The study was funded by the NIH. “
I would say that in my opinion, it’s a really important step in looking at the therapeutic potential of cannabinoids in chronic conditions.”
The study was funded by the NIH.
It was published in the Journal of Clinical Investigation.
Follow the latest health news from around the world in The World Health Organization.
More coverage of medical cannabis: Drug makers spend millions to boost cannabis-derived medicines’ popularity Medical marijuana may be coming, but the new strain may not be ready for prime time.
That’s because the industry is in the midst of a boom.
The first phase of a three-year research project is under way, and the industry’s appetite for the drug is still growing.
“This is a very exciting time to be in the cannabis industry,” says Jonathan Boulanger, president and CEO of the National Center for Cannabis Research.
“It’s going to be a new kind of marijuana and an interesting time to watch its effects.”
The U.S. government has approved marijuana for medical use, and a handful of states are considering legalizing recreational use.
There are about 3.4 million patients registered with the government and more than 100 million people in the United States have some form of chronic pain, according the National Institute on Drug Abuse.
Some of the most common types of chronic conditions are osteoarthritis, fibromyalgia and multiple sclerosis.
But cannabis has also been shown to help people with PTSD, seizures, severe depression, anxiety and chronic fatigue.
A new strain, called Triticum Sativa, or TSA, has been approved for the treatment of some forms of cancer.
It has shown promise for treating multiple sclerosis and